SERPING1 and hereditary angioedema: A highly-concentrated human plasma-derived C1-INH for subcutaneous injection (C1-INH [SC], HAEGARDA®, CSL Behring) has been approved by regulatory agencies for long-term prevention of HAE attacks in adolescents and adults based on the phase 3 COMPACT study [5, 13].